Dental Care for Veterans Act
Summary
The Dental Care for Veterans Act (HR210) expands VA dental eligibility to all enrolled veterans, creating an estimated $5-10B annual procurement opportunity for dental suppliers. The bill has 95 cosponsors and passed committee hearings but no appropriations are authorized. HSIC and XRAY are the strongest structural beneficiaries given their pure-play dental exposure.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR210 creates a $5-10B annual VA dental procurement market but requires separate appropriations — no guaranteed spending.
- 2.HSIC and XRAY are pure-play dental suppliers that would directly benefit from expanded VA procurement; DHR's dental exposure is smaller relative to its diversified portfolio.
- 3.The bill has strong cosponsor support (95) and has advanced to hearings, but remains in committee with no floor vote scheduled.
- 4.Current stock prices for HSIC and XRAY show limited bill-driven momentum — implying the market has not priced in passage.
Market Implications
HSIC (Henry Schein) at $74.16 is down 4.36% in the past 7 days, trading near the middle of its 52-week range ($61.95-$89.29). The stock has been range-bound with no breakout, indicating the market does not yet assign material probability to HR210's passage. If the bill gains floor vote momentum, HSIC could re-rate toward its 52-week high given the potential $100-500M in annual revenue. XRAY (Dentsply Sirona) at $11.63 is down 2.35% in 7 days and is trading closer to its 52-week low ($9.85) than its high ($17.18). The stock is structurally undervalued relative to a bullish scenario. Both stocks face downside risk if the bill stalls—HSIC's downside is limited by its broader dental distribution business; XRAY's by its turnaround challenges. DHR at $179.06 is near its 52-week low and is more influenced by its life sciences and diagnostics segments than dental legislation.
Full Analysis
- What happened: HR210, the Dental Care for Veterans Act, would require the VA to provide dental care to all enrolled veterans, phased in over four years. Currently, only veterans with service-connected dental conditions qualify. The bill was introduced January 6, 2025, has 95 cosponsors, and held committee hearings on March 18, 2026. It remains in committee (House Veterans' Affairs) and has not been voted on the floor. 2) The money trail: The bill itself does not authorize any specific dollar amount—the $5-10B annual estimate is based on the Congressional Budget Office scoring of similar prior bills. Actual appropriations would require a separate funding bill. This means the revenue potential is real but contingent on subsequent legislative action. 3) Structural winners: Pure-play dental suppliers HSIC (Henry Schein) and XRAY (Dentsply Sirona) are the strongest beneficiaries because VA dental procurement would flow directly through their distribution and manufacturing channels. Diversified players like DHR (Danaher, which owns KaVo Kerr dental) have some exposure but dental is a smaller segment of their overall business (DHR's current price is $179.06, near its 52-week low of $175). CVS Health is not a direct beneficiary—VA dental procurement goes through dedicated dental suppliers, not retail pharmacies. 4) Market data: HSIC is at $74.16, down 4.36% over the past 7 days but still above its 52-week low of $61.95. The recent 7-day decline likely reflects broader market rotation rather than bill-specific news. XRAY is at $11.63, down 2.35% in 7 days, and near its 52-week low of $9.85. These valuations already price in limited near-term catalyst; the bill's progress would be a positive surprise. 5) Timeline: The bill must clear the House Veterans' Affairs Committee, then the full House, then Senate, then be signed into law. With 95 cosponsors (nearly 22% of the House), there is broad support but no guarantee of passage. Actual revenue for HSIC and XRAY would not begin until phased implementation starts, likely 1-2 years post-enactment.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Limited confirming evidence — causal thesis exists but few external signals
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Veterans SPORT Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.